Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary, Alpha Tau Medical Inc., has entered into a long-term lease agreement for a standalone building of over 14,000 rentable square feet in Hudson, New Hampshire, with the intention of erecting the Company’s second U.S. manufacturing site, alongside its first site in nearby Lawrence, Massachusetts.

“I am pleased that our planned expansion of global manufacturing capacity continues apace, as we push forward towards our first targeted U.S. FDA clearance, as we see rapidly growing clinician interest in Alpha DaRT around the world, and as we get ready for future commercialization,” said Alpha Tau CEO Uzi Sofer. “The Hudson site promises to be larger than our existing Lawrence site, and is expected to support our goals of materially scaling up capacity as well as achieving manufacturing redundancy. In parallel, we are also progressing with our expansion plan in Israel, with the addition of a second site at our future standalone headquarters in Jerusalem.”

Alpha Tau COO Amnon Gat added, “The Hudson site will be an important component of our future manufacturing footprint in the U.S. We anticipate initiating manufacturing of Alpha DaRT treatments at this facility within two years, if not sooner, and being able to manufacture nearly 1.8 million Alpha DaRT sources per year when it is up to full capacity. We would look to install this capacity in two or three phases, each phase only costing in the low single-digit millions to build out.”